Compare Neurocrine Biosciences Inc (NBIX) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while iShares 10 20 Year Treasury Bond ETF trades at $96.05. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | TLH | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Fixed Income |
52-Week High | $185.50 | $105.36 |
52-Week Low | $123.10 | $96.08 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
TLH trades at $96.52, down 0.09% on the day, with a bearish technical signal from moving averages but a neutral reading from oscillators. Recent corporate actions include dividend payments scheduled for 2026. Key support and resistance levels are tightly clustered around $96-$97. Financial ratios such as P/E, P/S, and ROE are not provided in the current data snapshot.
The outlook for TLH is clouded by the lack of recent fundamental data, making valuation difficult. Investment opportunity hinges on future earnings clarity and dividend sustainability. Risks include market volatility, macroeconomic pressures from rising bond yields and oil prices, and potential impacts from geopolitical tensions on broader equity sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
